title: Bone consequences of epilepsy and antiepileptic medications.
abstract: Childhood and adolescence are critical periods of skeletal mineralization. Peak bone mineral density achieved by the end of adolescence determines the risk for later pathological fractures and osteoporosis. Chronic disease and medication often adversely affect bone health. Epilepsy is one of the most common neurological conditions occurring in persons under the age of 21. Epilepsy may affect bone in a number of ways. Restrictions of physical activity imposed by seizures, cerebral palsy or other coexisting comorbidities adversely affect bone health. It has been observed that treatment with phenytoin and phenobarbital can be associated with rickets. More recently, established agents such as carbamazepine and valproate have been shown to be associated with decreased bone mineral density. The literature related to bone health in pediatric epilepsy is reviewed.
authors: Department of Neurology, University of Wisconsin-Madison, Madison 53792-5132, USA.
authors: Edgar A
authors: EA
authors: Samaniego
authors: Raj D
authors: RD
authors: Sheth
mesh_terms: D015502:Absorptiometry, Photon; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001846:Bone Development / Q000187:drug effects* / Q000502:physiology*; D002648:Child; D004827:Epilepsy / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D050071:Bone Density Conservation Agents; D014807:Vitamin D